CPL
DMAC icon

Capital & Planning LLC’s DiaMedica Therapeutics DMAC Stock Holding History

Capital & Planning LLC’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,001
Closed -$13.5K – 72
2026
Q1 		$13.5K Buy
+2,001
New +$15.9K 0.01% 90

Other funds holding DMAC

CLG
Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital & Planning LLC's DMAC Position: Q2 2026 in Review

Capital & Planning LLC sold out of DiaMedica Therapeutics (DMAC) in Q2 2026, closing a stake of 2,001 shares — an estimated $13.5K sold.

Capital & Planning LLC first reported a position in DMAC in Q1 2026 and held it in 1 quarter. The position peaked at $13.5K in Q1 2026. 89 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • Capital & Planning LLC reported no remaining DiaMedica Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Capital & Planning LLC sold 2,001 DiaMedica Therapeutics shares in Q2 2026, an estimated $13.5K.
  • Capital & Planning LLC first reported a position in DiaMedica Therapeutics in Q1 2026 and held it in 1 quarter.
  • Capital & Planning LLC's DiaMedica Therapeutics position peaked at $13.5K in Q1 2026.
  • 89 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on Capital & Planning LLC's 13F filing for Q2 2026, filed 2 Sep 2026.